Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
Por:
Iborra, M, Garcia-Morales, N, Rubio, S, Bertoletti, F, Calvo, M, Taxonera, C, Bosca-Watts, MM, Sierra, M, Mancenido, N, Beltran, B, Castillejo, ON, Garcia-Planella, E, Vera, I, Alba, C, Marti-Aguado, D, Ballester, MP, Cano-Sanz, N, Pajares-Villarroya, R, Cerrillo, E, Canada, A, Nos, P
Publicada:
20 oct 2020
Resumen:
Golimumab has demonstrated its long-term efficacy and safety in ulcerative colitis in clinical trials, but no data of long-term persistence has been published from real world. To estimate long-term persistence of golimumab, as well as factors associated with longer persistence, in patients with ulcerative colitis in real life. Observational multicentre study including adult patients with ulcerative colitis treated with golimumab and with at least twelve months of follow-up. We included 190 patients, 105 (55.26%) naive to anti-TNF, with mean disease duration of 9.32 +/- 8.09 years. Probability of persistence was 63%, 46%, 39% and 27% at 1, 2, 3 and 4 years, respectively. Persistence was lower in patients with primary failure to previous anti-TNF. Eighty-two (43.16%) patients needed dose intensification during follow-up, with a mean time until intensification of 8.03 +/- 8.64 months. Dose intensification and lower disease duration predicted higher persistence with golimumab (p=0.037 and p=0.008, respectively). During a follow-up of 17.25 +/- 15.83 months, 32 (16.5%) patients needed hospitalisation and 11 (6%) underwent colectomy. No unexpected adverse events were reported. Golimumab has demonstrated good persistence and safety profile for long treatment in ulcerative colitis patients.
Filiaciones:
Iborra, M:
Hosp Univ & Politecn La Fe, Dept Gastroenterol, Avinguda Fernando Abril Martorell 106, Valencia 46026, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Garcia-Morales, N:
Hosp Univ & Politecn La Fe, Dept Gastroenterol, Avinguda Fernando Abril Martorell 106, Valencia 46026, Spain
Rubio, S:
Complejo Hosp Navarra, Dept Digest Dis, Pamplona, Spain
Bertoletti, F:
Hosp Santa Creu & Sant Pau, Dept Gastroenterol, Barcelona, Spain
Calvo, M:
Hosp Univ Puerta Hierro, Dept Gastroenterol, Madrid, Spain
Taxonera, C:
Hosp Clin San Carlos, Dept Gastroenterol, Madrid, Spain
Bosca-Watts, MM:
Hosp Clin Univ, Dept Gastroenterol, Valencia, Spain
Sierra, M:
Complejo Asistencial Univ Leon, Dept Gastroenterol, Leon, Spain
Mancenido, N:
Hosp Univ Infanta Sofia, Dept Gastroenterol, Madrid, Spain
Beltran, B:
Hosp Univ & Politecn La Fe, Dept Gastroenterol, Avinguda Fernando Abril Martorell 106, Valencia 46026, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Castillejo, ON:
Complejo Hosp Navarra, Dept Digest Dis, Pamplona, Spain
Garcia-Planella, E:
Hosp Santa Creu & Sant Pau, Dept Gastroenterol, Barcelona, Spain
Vera, I:
Hosp Univ Puerta Hierro, Dept Gastroenterol, Madrid, Spain
Alba, C:
Hosp Clin San Carlos, Dept Gastroenterol, Madrid, Spain
Marti-Aguado, D:
Hosp Clin Univ, Dept Gastroenterol, Valencia, Spain
Ballester, MP:
Hosp Clin Univ, Dept Gastroenterol, Valencia, Spain
Cano-Sanz, N:
Complejo Asistencial Univ Leon, Dept Gastroenterol, Leon, Spain
Pajares-Villarroya, R:
Hosp Univ Infanta Sofia, Dept Gastroenterol, Madrid, Spain
Cerrillo, E:
Hosp Univ & Politecn La Fe, Dept Gastroenterol, Avinguda Fernando Abril Martorell 106, Valencia 46026, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Canada, A:
Hosp Univ & Politecn La Fe, Inst Invest Sanitaria, Dept Biostat & Bioinformat, Valencia, Spain
Nos, P:
Hosp Univ & Politecn La Fe, Dept Gastroenterol, Avinguda Fernando Abril Martorell 106, Valencia 46026, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Gold, Green Published
|